Vistagen Therapeutics, Inc. (VTGN) Stock Price & Analysis
Vistagen Therapeutics, Inc. (VTGN) rose 0.18% to USD 0.23 as of July 25, 2026 at 06:46 UTC, according to Nexqual real-time market data.
VTGN last closed at USD 0.23; the session ranged USD 0.22–0.23 on volume of 1,125,358 shares. Market capitalization is $9.29M, with a 52-week range of USD 0.2–5.14 (NCM). Source: Nexqual, July 25, 2026 at 06:46 UTC.
Key Statistics (as of July 25, 2026 at 06:46 UTC)
| Price | USD 0.23 |
|---|---|
| Change | ▲ 0.18% (up) |
| Previous Close | USD 0.23 |
| Open | USD 0.22 |
| Day Range | USD 0.22 – 0.23 |
| 52-Week Range | USD 0.2 – 5.14 |
| Volume | 1,125,358 shares |
| Market Cap | $9.29M |
| Exchange | NCM |
Technical Analysis (VTGN)
Nexqual's technical model rates VTGN "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:46 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 34.1 (neutral) |
| vs SMA50 | Below (USD 0.49) |
| MACD | -0.08 (negative) |
Analyst Ratings (VTGN)
Wall Street analysts rate VTGN "None" based on 2 analysts, with a mean price target of USD 1 (range USD 1–1), per Nexqual as of July 25, 2026 at 06:46 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 1 |
| High Target | USD 1 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 0 / 4 / 0 |
Earnings (VTGN)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.37 |
| Revenue Estimate | $166,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.37 vs est -0.27 ▼ miss |
| 2025-12-31 | USD -0.45 vs est -0.49 ▲ beat |
| 2025-09-30 | USD -0.54 vs est -0.44 ▼ miss |
| 2025-06-30 | USD -0.47 vs est -0.44 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
Financials & Fundamentals (VTGN)
| Total Revenue | $1.27M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -3595.05% |
| Profit Margin | +0.00% |
| ROE | -131.59% |
| Debt / Equity | 2.94 |
| Current Ratio | 3.67 |
| Total Cash | $45.40M |
| Total Debt | $1.04M |
| Free Cash Flow | $-40.50M |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
Financial Health Score (VTGN)
Nexqual rates Vistagen Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:46 UTC.
| Growth | Strong — Revenue +161% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $45M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$40M, burning cash |
| Efficiency | Critical — ROE -132%, ROA -67.8% |
Ownership (VTGN)
| Insider Ownership | +0.29% |
|---|---|
| Institutional Ownership | +40.89% |
| Shares Outstanding | 41.03M |
| Float | 35.04M |
| Short % of Float | +3.90% |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
Leadership (VTGN)
Vistagen Therapeutics, Inc. is led by Shawn K. Singh, President, CEO & Director, per Nexqual as of July 25, 2026 at 06:46 UTC.
| President, CEO & Director | Shawn K. Singh |
|---|---|
| CFO & Treasurer | Nick B. Tressler (age 52) |
| Chief Operating Officer | Joshua S. Prince (age 54) |
| Senior Vice President of Investor Relations | Mark Adrian McPartland (age 59) |
| Vice President of Communications | Michelle Peters Wellington |
Major Backers & Investors (VTGN)
Notable institutional backers of Vistagen Therapeutics, Inc. include Orbimed Advisors LLC., TCG Crossover Management, LLC, Adar1 Capital Management, LLC , according to Nexqual as of July 25, 2026 at 06:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 7.46% |
| TCG Crossover Management, LLC | 6.52% |
| Adar1 Capital Management, LLC | 1.83% |
| Stempoint Capital LP | 1.5% |
| Acadian Asset Management. LLC | 1.44% |
| Ikarian Capital, LLC | 1.27% |
| Two Sigma Investments, LP | 1.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.68% |
| BlackRock | 1.33% |
| Geode Capital | 1.1% |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
From Vistagen Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-06-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
- The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
- It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
| OTLK | Outlook Therapeutics, Inc. | USD 1.41 | ▲ 4.85% |
| TENX | Tenax Therapeutics, Inc. | USD 14.53 | ▼ 1.76% |
| XBIO | Xenetic Biosciences, Inc. | USD 2.64 | ▼ 1.12% |
| VSTM | Verastem, Inc. | USD 6.05 | ▲ 2.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:46 UTC. This page is informational and not investment advice.